PRIDE Industries Achieves AS9100 Certification, Strengthening its Position in Aerospace and Defense Manufacturing
November 05, 2024 09:00 ET
|
PRIDE Industries
Roseville, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- PRIDE Industries, the nation’s leading employer of people with disabilities, proudly announces that its Manufacturing and Logistics Services...
Bionomics Receives Milestone Payment of AUS$1M from Carina Biotech for BNC101 Partnered Legacy Oncology Program
November 04, 2024 16:15 ET
|
Bionomics Ltd
ADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel,...
SoldierStrong, USC Institute for Creative Technologies Sign License Agreement for Battle Buddy
November 04, 2024 09:00 ET
|
SoldierStrong
STAMFORD, Conn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- SoldierStrong, a national nonprofit dedicated to helping veterans take their next steps forward in life after service through the donation of...
Janover Enters Licensing Agreement with Leading Commercial Real Estate Services Firm to Provide AI Client Engagement Tools
November 04, 2024 08:00 ET
|
Janover Inc.
BOCA RATON, FL, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Janover Inc. (Nasdaq: JNVR) (“Janover” or the “Company”), an AI-enabled platform connecting the commercial real estate industry, is pleased to...
Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan
November 04, 2024 07:35 ET
|
Y-mAbs Therapeutics, Inc.
NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases
November 04, 2024 07:00 ET
|
Ascendis Pharma
- Collaboration leverages Ascendis’ proprietary TransCon™ technologies and Novo Nordisk’s expertise in cardiometabolic diseases - Once-monthly GLP-1 receptor agonist will be the collaboration’s...
AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics
October 31, 2024 08:00 ET
|
EvolveImmune
NORTH CHICAGO, Ill. and BRANFORD, Conn., Oct. 31, 2024 (GLOBE NEWSWIRE) -- AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics to...
InterDigital signs license agreement with OPPO Group
October 29, 2024 04:00 ET
|
InterDigital, Inc.
WILMINGTON, Del., Oct. 29, 2024 (GLOBE NEWSWIRE) -- InterDigital, Inc. (Nasdaq: IDCC), a mobile, video and AI technology research and development company, today announced that it has signed a new...
SWA Lithium and Koch Technology Solutions Sign License for First Commercial DLE Project in North America
October 28, 2024 08:00 ET
|
Standard Lithium
EL DORADO, Ark., Oct. 28, 2024 (GLOBE NEWSWIRE) -- SWA Lithium, the Joint Venture between Standard Lithium and Equinor which is developing the South West Arkansas Project (“SWA” or the “Project”),...
EnWave Signs License Agreement, Equipment Purchase Agreement and Referral Agreement with CNTA of Spain
October 23, 2024 09:00 ET
|
EnWave Corporation
VANCOUVER, British Columbia, Oct. 23, 2024 (GLOBE NEWSWIRE) -- EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company") announced today that it has signed a license agreement (the...